ESR1 and breast carcinoma: The study population included 6729 women diagnosed with a second breast cancer (5606 women with estrogen receptor–positive second cancer and 1123 women with estrogen receptor–negative second cancer) as well as 357 204 women with a first breast cancer (303 837 women with estrogen receptor–positive cancer and 53 367 women with estrogen receptor–negative cancer).